Steinfield Sara R, Stenn Daniel F, Chen Helen, Kalisch Bettina E
Department of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.
Collaborative Specialization in Neuroscience Program, University of Guelph, Guelph, ON N1G 2W1, Canada.
Pharmaceuticals (Basel). 2025 Apr 30;18(5):659. doi: 10.3390/ph18050659.
Alzheimer's disease (AD) is a neurodegenerative disease marked by the accumulation of toxic amyloid-beta (Aβ) oligomers. These oligomers are thought to cause synaptic dysfunction and contribute to neurodegeneration. CT1812 is a small-molecule sigma-2 receptor antagonist that is currently being investigated and tested as a potential disease-modifying treatment for AD. CT1812 acts by displacing Aβ oligomers into the cerebrospinal fluid and preventing their interaction with receptors on neurons. Preclinical studies and early clinical trials of CT1812 show promising results and provide evidence for its potential to slow AD progression. This review outlines the role of Aβ oligomers in AD, CT1812's mechanism of action, and the effectiveness and limitations of CT1812 based on preclinical and clinical studies.
阿尔茨海默病（AD）是一种神经退行性疾病，其特征是有毒的β-淀粉样蛋白（Aβ）寡聚体的积累。这些寡聚体被认为会导致突触功能障碍并促进神经退行性变。CT1812是一种小分子σ-2受体拮抗剂，目前正在作为AD的一种潜在疾病修饰治疗方法进行研究和测试。CT1812的作用方式是将Aβ寡聚体置换到脑脊液中，并阻止它们与神经元上的受体相互作用。CT1812的临床前研究和早期临床试验显示出有希望的结果，并为其减缓AD进展的潜力提供了证据。这篇综述概述了Aβ寡聚体在AD中的作用、CT1812的作用机制，以及基于临床前和临床研究的CT1812的有效性和局限性。
